deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 10-arm NCT03020030

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Sponsor: Dana-Farber Cancer Institute

Conditions Acute Lymphoblastic Leukemia, Pediatric
Interventions CYTARABINE Cyclophosphamide DASATINIB DEXAMETHASONE Dexrazoxane Doxorubicin ETOPOSIDE Erwinia asparaginase HYDROCORTISONE LEUCOVORIN CALCIUM MERCAPTOPURINE METHOTREXATE NELARABINE Pegaspargase Vincristine
Updated 22 times since 2017 Last updated: Jan 21, 2026 Started: Mar 3, 2017 Primary completion: Nov 30, 2026 Completion: Nov 30, 2034
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03020030, this PHASE3 trial focuses on Acute Lymphoblastic Leukemia, Pediatric and remains ongoing. Sponsored by Dana-Farber Cancer Institute, it has been updated 22 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Feb 2018 · 5 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Jun 2019 · 10 months · monthly snapshot~Jun 2019 – ~Feb 2020 · 8 months · monthly snapshot~Feb 2020 – ~Oct 2020 · 8 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Feb 2022 · 4 months · monthly snapshot~Feb 2022 – ~Jul 2022 · 5 months · monthly snapshot~Jul 2022 – ~Dec 2022 · 5 months · monthly snapshot~Dec 2022 – ~Jun 2023 · 6 months · monthly snapshot~Jun 2023 – ~Dec 2023 · 6 months · monthly snapshot~Dec 2023 – ~Jun 2024 · 6 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Aug 2025 · 6 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

22 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE3

  2. Sep 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE3

  3. Aug 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Feb 2025 — Aug 2025 [monthly]

    Active Not Recruiting PHASE3

  5. Sep 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE3

▶ Show 17 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  2. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Dec 2023 — Jun 2024 [monthly]

    Active Not Recruiting PHASE3

  4. Jun 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE3

  5. Dec 2022 — Jun 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  6. Jul 2022 — Dec 2022 [monthly]

    Recruiting PHASE3

  7. Feb 2022 — Jul 2022 [monthly]

    Recruiting PHASE3

  8. Oct 2021 — Feb 2022 [monthly]

    Recruiting PHASE3

  9. Jan 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

  10. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  11. Feb 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  12. Jun 2019 — Feb 2020 [monthly]

    Recruiting PHASE3

  13. Aug 2018 — Jun 2019 [monthly]

    Recruiting PHASE3

  14. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  15. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  16. Sep 2017 — Feb 2018 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  17. Feb 2017 — Sep 2017 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dana-Farber Cancer Institute
  • Servier
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations